Conjunctivitis, Viral

MILAN, Dec. 5, 2024 /PRNewswire/ -- NTC, an international R&D focused pharmaceutical company headquartered in Italy, presents positive results from Phase II MIRAKLE study, a multicentre, randomized, blinded-assessor, phase II non-inferiority study evaluating the efficacy and tolerability of NTC014 (quinolone antibiotic + NSAID in eye drops solution) in the treatment of bacterial conjunctivitis in adults. Despite NTC014, due to its simplified therapeutic regimen, has been administered at a lower posology than the antibiotic comparator –25% of less antibiotic administered - the main results showed the non-inferiority of NTC014 eye drops vs antibiotic alone in microbiological eradication, with unexpected efficacy results even against pathogens classified as Intermediate or Resistant to the quinolone antibiotic under study. "These interim findings reaffirm that NTC014 is eligible to be a new treatment for bacterial conjunctivitis", Alessandro Colombo, Chief Scientific Officer, NTC, states. "We aim at demonstrating with robust clinical evidence value and potential for NTC014, considering also that this drug responds to our mission to contribute to fighting antibiotic resistance by using less antibiotics, for a shorter treatment duration with no limitation of usage, also in case of non-confirmation of bacterial etiology." "We are encouraged by the overall results of the Mirakle study", says Riccardo Carbucicchio, Chief Executive Officer in NTC, "NTC 014 is first in class combination worldwide of an antibiotic and an NSAID. Given the significant unmet medical need, NTC014 aims to provide physicians with an effective treatment for moderate-severe bacterial conjunctivitis, a common eye infection. We believe that NTC 014 has a great potential and we aim to finalize the commercial partnering for this asset in most countries of the world before end of 2025. We do not exclude to develop this asset for surgical use too". Conjunctivitis is a common disease in Western Countries and imposes economic and social burdens. Viral conjunctivitis is the most common cause of infectious conjunctivitis both overall and in the adult population, bacterial conjunctivitis is the second most common cause and is responsible for the majority (50%-75%) of cases in children. NTC has already successfully developed and launched the first combination of a quinolone and steroid for post cataract surgery1, licensed in almost 90 countries and currently marketed in 60 countries, in Europe, Asia, Americas and Africa. About NTC A pharmaceutical company headquartered in Milan - Italy, with distributors and partners in more than 100 countries, engaged in research, development, registration, and commercialization of drugs, medical devices, and food supplements in ophthalmology, and other therapeutic areas including pediatrics, gynecology, and gastroenterology. NTC offers more than 200 partners innovative and high quality standard pharmaceutical products. For more information, please visit 1. Bandello F., et al. One week of levofloxacin plus dexamethasone eye drops for cataract surgery: an innovative and rational therapeutic strategy. Eye (2020), Logo - SOURCE NTC Srl WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

NTC presents positive results from Phase II Mirakle study evaluating an innovative drug for bacterial conjunctivitis Milan, December 5, 2024 – NTC, an international R&D focused pharmaceutical company headquartered in Italy, presents positive results from Phase II MIRAKLE study, a multicentre, randomized, blinded-assessor, phase II non-inferiority study evaluating the efficacy and tolerability of NTC014 (quinolone antibiotic + NSAID in eye drops solution) in the treatment of bacterial conjunctivitis in adults. Despite NTC014, due to its simplified therapeutic regimen, has been administered at a lower posology than the antibiotic comparator –25% of less antibiotic administered - the main results showed the non-inferiority of NTC014 eye drops vs antibiotic alone in microbiological eradication, with unexpected efficacy results even against pathogens classified as Intermediate or Resistant to the quinolone antibiotic under study. “These interim findings reaffirm that NTC014 is eligible to be a new treatment for bacterial conjunctivitis”, Alessandro Colombo, Chief Scientific Officer, NTC, states. “We aim at demonstrating with robust clinical evidence value and potential for NTC014, considering also that this drug responds to our mission to contribute to fighting antibiotic resistance by using less antibiotics, for a shorter treatment duration with no limitation of usage, also in case of non-confirmation of bacterial etiology.” “We are encouraged by the overall results of the Mirakle study”, says Riccardo Carbucicchio, Chief Executive Officer in NTC, “NTC 014 is first in class combination worldwide of an antibiotic and an NSAID. Given the significant unmet medical need, NTC014 aims to provide physicians with an effective treatment for moderate-severe bacterial conjunctivitis, a common eye infection. We believe that NTC 014 has a great potential and we aim to finalize the commercial partnering for this asset in most countries of the world before end of 2025. We do not exclude to develop this asset for surgical use too”. Conjunctivitis is a common disease in Western Countries and imposes economic and social burdens. Viral conjunctivitis is the most common cause of infectious conjunctivitis both overall and in the adult population, bacterial conjunctivitis is the second most common cause and is responsible for the majority (50%-75%) of cases in children. NTC has already successfully developed and launched the first combination of a quinolone and steroid for post cataract surgery, licensed in almost 90 countries and currently marketed in 60 countries, in Europe, Asia, Americas and Africa. About NTC A pharmaceutical company headquartered in Milan - Italy, with distributors and partners in more than 100 countries, engaged in research, development, registration, and commercialization of drugs, medical devices, and food supplements in ophthalmology, and other therapeutic areas including pediatrics, gynecology, and gastroenterology. NTC offers more than 200 partners innovative and high quality standard pharmaceutical products. For more information, please visit www.ntcpharma.com

WEDNESDAY, July 10, 2024 -- More than two-thirds of children with conjunctivitis have a prescription filled for topical antibiotics within one day of an ambulatory care visit, according to a research letter published online June 27 in JAMA Ophthalmology . Daniel J. Shapiro, M.D., M.P.H., from the University of California, San Francisco, and colleagues examined prescription of topical antibiotic treatment and the association of treatment with subsequent health care use among individuals aged 1 to 17 years with ambulatory care encounters who had a conjunctivitis diagnosis. A total of 44,793 ambulatory care encounters were included. The researchers found that after 69 percent of encounters, topical antibiotics were dispensed within one day. Topical antibiotics were dispensed less frequently after visits to eye clinics, for children aged 6 to 11 years, and for viral conjunctivitis (34, 66, and 28 percent, respectively). After 3.2 percent of index encounters, ambulatory care revisits for conjunctivitis occurred within 14 days. After 1.4 percent of index encounters, all-cause revisits with a same-day antibiotic dispensation occurred. No association was seen for topical antibiotic treatment with ambulatory care revisits for conjunctivitis or revisits with same-day topical antibiotic dispensation in a multivariable analysis. Hospitalizations for conjunctivitis and emergency department revisits occurred for 0.03 and 0.12 percent of children, respectively, with no differences seen across exposure groups. "Revisits and new antibiotic dispensations were rare, regardless of initial topical antibiotic treatment, suggesting that not receiving antibiotics may not be associated with additional health care use," the authors write. "Given that antibiotics may not be associated with improved outcomes or change in subsequent health care use and are associated with adverse effects and antibiotic resistance, efforts to reduce overtreatment of acute infectious conjunctivitis are warranted."